Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Leukemia. 2016 Nov 14;31(5):1196–1205. doi: 10.1038/leu.2016.329

Figure 1. JUN supports AML cell survival and disease propagation in vivo.

Figure 1

A. THP-1 cells expressing shNT or shJUN-1 & -2 were analyzed by western-blot with the indicated antibodies. B. THP-1 cells expressing shNT or shJUN were seeded at equal densities and then subsequently monitored for cell growth & survival by MTS at days 0, 2 and 4. C. THP-1 cells from each shRNA condition were assessed for BrdU incorporation by flow cytometry. D. Five days after the introduction of shRNAs, THP-1 cells expressing shNT or shJUN-1 or -2 were stained with Annexin V and propidium iodide (PI) and analyzed for cell death by flow cytometry. E & F. FACS-purified GFP+ MLL-AF9 leukemia cells from each shRNA condition were assessed by western blot with the indicated antibodies (E.) as well as colony formation in methylcellulose (F.). G. Kaplan-Meier survival curve analysis of mice transplanted with purified MLL-AF9 cells expressing shNT (blue curve, n = 8) or Jun-2 (red curve, n=9)-targeting shRNAs (P = 0.0003). (** P < 0.01, **** P < 0.0001 vs control).